Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 11/20 | 0.42 |
| ▸ | ESR1 | P03372 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781540 | 1.00 | ESR2 (0.42) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL1780215 | 1.00 | ESR2 (0.42) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL742590 | 0.84 | ESR2 (0.52) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL1787869 | 0.82 | HTR2C (0.36) | ESR2ESR1CYP3A4CYP2C9HTR2C | |
| SCHEMBL1787872 | 0.82 | HTR2C (0.36) | ESR2ESR1CYP3A4CYP2C9HTR2C | |
| SCHEMBL12603782 | 0.82 | SPHK1 (0.41) | ESR2CYP2C9HTR2CSPHK1 | |
| SCHEMBL12603843 | 0.82 | SPHK1 (0.41) | ESR2CYP2C9HTR2CSPHK1 | |
| SCHEMBL1787895 | 0.82 | HTR2C (0.36) | ESR2ESR1CYP3A4CYP2C9HTR2C | |
| SCHEMBL15437191 | 0.82 | HTR2C (0.36) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL15437190 | 0.82 | HTR2C (0.36) | ESR2ESR1CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053428-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-21 | — | — | US | disclosed |
| US-20170260139-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | US | disclosed |
| US-9688636-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-2197551-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-12-28 | — | — | EP | disclosed |
| EP-2875003-B1 | NEW 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS UND THEIR USE | Bayer Pharma AG (DE) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015095515-A1 | SGC ACTIVATORS FOR THE TREATMENT OF GLAUCOMA | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20150148376-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| EP-2875003-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-8981104-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-17 | — | — | US | disclosed |
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-30 | — | — | US | disclosed |
| WO-2014012934-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-23 | — | — | WO | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| CN-101939053-A | Soluble guanylate cyclase activators | MERCK SHARP & DOHME | 2011-01-05 | — | — | CN | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | TNNT2, TNNI3, FABP3 | ESR2 1818/4885ESR1 4186/4885CYP3A4 684/4885 |
| US-10053428-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | TNNT2, TNNI3, FABP3 | ESR2 1595/4885ESR1 3999/4885CYP3A4 574/4885 |
| US-20170260139-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | TNNT2, TNNI3, FABP3 | ESR2 1818/4885ESR1 4186/4885CYP3A4 684/4885 |
| US-20150148376-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | TNNT2, TNNI3, FABP3 | ESR2 1818/4885ESR1 4186/4885CYP3A4 684/4885 |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | ESR2 823/4885ESR1 932/4885CYP3A4 3506/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | ESR2 823/4885ESR1 932/4885CYP3A4 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.